Eliem Therapeutics Inc Aktie News

PHILADELPHIA , April 15, 2024 /PRNewswire/ -- Kaskela Law LLC, announces that it is investigating Eliem Therapeutics, Inc. (NASDAQ: ELYM) ("Eliem") on behalf of the company's shareholders. The investigation seeks to determine whether Eliem issued false and misleading statements and/or failed to disclose material facts to investors in connection with recent corporate actions, thereby violating t...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Eliem Therapeutics, Inc. (NASDAQ: ELYM) and Tenet Medicines, Inc. is fair to Eliem shareholders. Halper Sadeh encourages Eliem shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersade...

Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivalents, including $120 million from a concurrent private placement of common stock from leading life sciences investors Combined company to focus on clinical development of lead product candidate, TNT...

SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the determination to halt further development of its Kv7 program and to conduct a comprehensive exploration of strategic alternatives focuse...

Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose

Initiated Phase 1 pharmacokinetic trial for ETX-155 with expected results in Q4 2022

Shares of Eliem Therapeutics Inc. ELYM, -11.51% tumbled 20.0% in premarket trading on Tuesday after the company said it will discontinue development of its treatment for lumbosacral radicular pain after a Phase 2a clinical trial didn't yield strong enough results. Eliem said it has enough capital to fund the development of other therapies and its operations through mid-2024.

Topline data from the Phase 2a clinical trial are expected in the third quarter of 2022